Genmab — April 2020
-
Jeg er også spændt. Nogen herinde har jo mendt at ikke covid19 patienter kommer til at lide under den manglende kapacitet. men jeg har nu svært ved at tro at kræftpatienter ikke kan få deres behandling.
-
Måske man vil undlade at give nye første line patienter dara/rev/dex. Så de kun får rev/dex eller bor/revdex?
-
dara skal jo fortsat gives IV medens rev og bor er tabletter.
-
ok tak Bulder. Så hvis der skal spares mandetimer på hospitalet, så kan de vælge kun at give rev/dex i første linie indtil der er bedre kapacitet. Det er det vi ikke ved, og kan betyde lidt mindre dara omsætning i Q1 2020.
-
Så er vi tilbage i den "den ganle" trendkannal. https://nbg1.your-objectstorage.com/proinvestor-dev/forum/boards/m83556_bundvending.jpg
-
Ja, men hvor mange aktier blev handlet i efter markedet?
-
we had this before in june last year https://twitter.com/MM_Hub/status/1139913117272555520
-
Blood - Daratumumab Plus CyBorD for Patients With Newly Diagnosed AL Amyloidosis: Safety Run-in Results of ANDROMEDA https://ashpublications.org/blood/article-abstract/doi/10.1182/blood.2019004460/454281/Daratumumab-Plus-CyBorD-for-Patients-With-Newly?redirectedFrom=fulltext
-
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind